Syntara Limited (ASX:SNT) Receives FDA Fast Track Designation for SNT-5505
Syntara Limited (ASX:SNT) secures FDA Fast Track for its myelofibrosis treatment SNT-5505, accelerating its development towards becoming a new standard of care.
Category: ASX-SNT
Syntara Limited
Syntara Limited (ASX:SNT) Expands Skin Scarring Program with SNT-9465
Syntara Limited (ASX:SNT) expands its skin scarring program with the new SNT-9465 drug, initiating Phase 1a/b trials in 2025.